News
A "nightmare bacteria" is surging while investment in antibiotics lags
11+ hour, 18+ min ago (533+ words) Experts are sounding the alarm about the rise in drug-resistant superbugs and urging more action. The explosive rise of the superbug is reemphasizing the need for therapies to fight the stubborn infections." At the time, patients who developed infections caused…...
HHS, responding to China's rise, moves to fast-track early drug research
22+ hour, 56+ min ago (305+ words) A series of newly planned reforms are designed to entice companies to start early trials in the U. S. rather than overseas. U. S. drugmakers have increasingly looked to China to source new experimental medicines, taking advantage of heavy government life sciences investment and…...
Why ivermectin is in the limelight again
1+ week, 1+ day ago (532+ words) As patient interest rises for using the antiparasitic drug in cancer, doctors are urging caution to see if the science catches up with the hype. Proponents and detractors largely agree on one point " there's not enough clinical evidence to support…...
Corvus CEO thinks his next blockbuster is an ITK inhibitor
1+ week, 2+ day ago (527+ words) It's like "Rituxan all over again," said CEO Richard Miller who believes Corvus' lead candidate could make an impact in both cancer and autoimmune diseases. Corvus Pharmaceuticals' founder and CEO Dr. Richard Miller isn't as interested in simply making incremental…...
How Lilly is defending its GLP empire
1+ week, 2+ day ago (641+ words) Eli Lilly's recent deal with Hanmi Pharm is another step in the drugmaker's quest to grow its GLP franchise beyond weight loss. As the race to develop next-generation GLP therapies heats up, Eli Lilly is laying the groundwork to grow…...
The biotech market is rebounding. So where are the executive jobs?
1+ week, 3+ day ago (571+ words) The industry is showing favorable economic signs, but biotech companies are still taking a measured approach to hiring leaders. Pharma M&A deals are up and layoffs are trending down. But executive hiring is still lagging, according to Leslie Loveless,…...
Astellas taps AI to reshape clinical programs as rising stars emerge
1+ week, 6+ day ago (794+ words) As it prepares to compete in the KRAS arena, the Japanese pharma has retooled its approach to clinical development. Astellas Pharma has been on a quest to transform its approach to drug development in the last few years with the…...
Competition is brewing between ADCs and bispecifics
2+ week, 11+ hour ago (769+ words) The competing modalities are each gaining traction in lung cancer. But will they ultimately become allies? Two therapies are positioned to become fierce rivals in non-small cell lung cancer: ivonescimab, a bispecific antibody drug, and sac-TMT, an antibody-drug conjugate." And…...
Amid a flurry of biotech deals, China looks to keep innovation at home
2+ week, 1+ day ago (886+ words) The country's new regulatory pathway promises to accelerate access to advanced therapies for Chinese patients, but may change the licensing game for foreign companies. Personalized cancer treatments, cell and gene therapies and regenerative medicine often don't fit neatly into a…...
With a promising MASH asset, muscle-sparing GLP-1 and new CEO, Rivus gets ready to make its mark
2+ week, 2+ day ago (910+ words) Rivus Pharmaceuticals" CEO Jorge Bartolome said the biotech is on track to build a "truly differentiated" cardio metabolic portfolio. Welcome to First 90 Days, a series dedicated to examining how pharma executives are planning for success in their new roles. Today,…...